Navigation Links
AHF Criticizes Tibotec Over Steep Price for Newest AIDS Drug, Etravirine
Date:1/21/2008

Following FDA Approval, Company Announces $7,800 Wholesale Price for

Lifesaving Drug

LOS ANGELES, Jan. 21 /PRNewswire-USNewswire/ -- AIDS Healthcare Foundation (AHF) today urged Tibotec Pharmaceuticals Ltd., a division of Johnson & Johnson, to reconsider and reduce its steep price for its newest AIDS drug, etravirine (TMC 125), a non-nucleoside reverse transcriptase inhibitor, (NNRTI), which received Food and Drug Administration (FDA) approval on Friday after a fast track or 'priority review' and approval process granted to companies for medications and therapies intended to treat life-threatening illnesses such as AIDS. Immediately following FDA approval of the drug, which Tibotec will sell under the brand name Intelence, Reuters reported that the drug's wholesale cost will be $5.45 per tablet. At the approved dose of two tablets twice per day, a 30-day supply would be $654-or close to $8,000 per patient, per year (PPY) wholesale cost.

"We commend Tibotec for the development of this promising new HIV/AIDS drug, but strongly urge them to immediately reconsider and price this life- saving AIDS medicine more fairly," said Michael Weinstein, AIDS Healthcare Foundation President. "As with many AIDS drugs before it, the cost of Intelence will simply be out of the price range for most AIDS patients and threatens to further stress Medicaid and AIDS Drug Assistance Programs nationwide. Just last week, Governor Arnold Schwarzenegger announced plans to cut $7 million dollars from California's ADAP, a program that helps low-income Californians living with HIV/AIDS access such lifesaving drugs. AIDS drugs are priced at the maximum the market will bear, regardless of production costs. It appears Tibotec is once again following suit with the steep price of its newest AIDS drug."

Tibotec drew earlier criticism from AIDS advocates back in June 2006 after it received FDA approval for its Protease Inhibitor, Prezista (daruna
'/>"/>

SOURCE AIDS Healthcare Foundation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Kmart Lowers Flu Shot Price to $10
2. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...WYORK,Nov.25/PRNewswire/--Reportlinker.comannounce...ogue: ,, MammographyEquipment-AGlobalMarketPe...64330/Mammography-Equipment---A-Global-Market-Pers...nindustrializedaswellasdevelopingnationsisaprincip...obally,escalatingawarenessaboutbreastcancerhasallo...
(Date:11/25/2009)...APELHILL,N.C.,Nov.25/PRNewswire/--CempraPharmaceut...esidentandchiefexecutiveofficer,willpresentatthePi...EST,December1,2009,atTheNewYorkPalaceHotelinNewYor...y,stwoleadingantibioticclinicalprogramsforthetreat... AboutCempraPharmaceuticals ,, Foundedin2006,C...
(Date:11/25/2009)...UNTAINVIEW,Calif.,Nov.25/PRNewswire/-- ChemoCentr...romtheCompany,sPROTECT-1(theProspectiveRandomizedO...et-EN(TM)(CCX282-B)inpatientswithmoderate-to-sever...vorablesafetyandtolerabilityprofile.Thestudydemons...seaseseverityasdefinedasa70-pointdecreaseintheCroh...
Breaking Medicine Technology:Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5Boston University Periodontal Study on Imagenetix Compound Published in The Journal of Periodontology 13525 1Boston University Periodontal Study on Imagenetix Compound Published in The Journal of Periodontology 13525 2Boston University Periodontal Study on Imagenetix Compound Published in The Journal of Periodontology 13525 3Cosmetic Use of Sculptra Now FDA Approved 54306 1Cosmetic Use of Sculptra Now FDA Approved 54306 2Cosmetic Use of Sculptra Now FDA Approved 54306 3Cosmetic Use of Sculptra Now FDA Approved 54306 4Fountain Healthy Aging Inc Announces 245 000 000 Equity Line Of Credit Investment Secured 54304 1Fountain Healthy Aging Inc Announces 245 000 000 Equity Line Of Credit Investment Secured 54304 2Fountain Healthy Aging Inc Announces 245 000 000 Equity Line Of Credit Investment Secured 54304 3
...ov. 26 Surface Logix, Inc. today announced,that J... will present an,update of the company,s drug deve...Health Care Conference being held November 27-29, ...oney,s presentation will take place,on Wednesday, ...currently has two programs in human clinical trial...
... Nov. 23 At a media event held today at the,Dello... prominent lasik,surgeons Drs. Joseph and Jeffrey ... by Swiss laser maker Alcon, which goes "beyond Cu...duced laser eye surgery to the nation,in 1990, he ...k evolution,leading the implementation of procedur...
Other Medicine Technology:
(Date:11/27/2009)..., NEUILLY-SUR-SEINE,France,Nov.27/PRNewswire/--Te...clingteamdedicatedtoethicalsportinganddevelopingth...atitwillbecomeTeamGarmin-Transitionswiththeadditio...tionsOpticalistheworld,sleadingmanufacturerofadapt...nologyinthewidestselectionofspectaclelensessuchasT...
(Date:11/27/2009)... XenaCare Holdings has announc...thritis Foundation, one of the largest nonprofit o...ublic health education. , ...aCare Holdings, Inc. (OTCBB: XCHO), a company spec...of consumer healthcare products, has announced tod...
(Date:11/27/2009)...ng rates to bring unprecedented medical, economic ... 27 (HealthDay News) -- The number of people with ...e over the next 25 years, a new study predicts. ,...1 million people with the disease, up from 23.7 mi...reating people with diabetes will triple, the stud...
(Date:11/27/2009)... Voyant Health™ announce...an) has licensed its TraumaCad Enterprise orthoped...rkflow solution. , (PRWEB...ced today that Spectrum Health (Grand Rapids, Mich...edic templating solution and its TraumaCad Extend ...
(Date:11/27/2009)... Specialist manufacturers who ...cts are saving millions of dollars by bringing in ...cess. Increasing numbers of pro-active medical man...s at the concept stage of their projects, ensuring... design processes or potentially outdated technolo...
Breaking Medicine News(10 mins):Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4
...LLE, Pa., Dec. 21 RESPIRONICS, INC.,(Nasdaq: RES...ve merger,agreement pursuant to which Royal Philip... commence a tender offer to acquire all of the out... a,premium of approximately 31% over Respironics, ...
... study finds that most general surgeons do not dis...breast cancer treatment. The analysis shows that o...or breast conserving surgery have such discussions...nstruction has increased treatment choices for wom...
...Calif., Dec. 20 ISTA Pharmaceuticals,Inc. (Nasdaq...ed a New Drug,Application (NDA) to the U.S. Food a...ce-daily). The Company is seeking approval for Xib...opical non-steroidal anti-inflammatory compound fo...
...om Community Will Fund 20 Percent of Cost for New ...undation announced that it has reached its $50 mil...mportant philanthropic effort Sharp has ever,under...com/cgi-bin/prnh/20071220/DC10448 ), "It,s only ...
...ON, Dec. 20 Today URAC called for,comments on maj...alth Web,Site, HIPAA Privacy (Business Associate a...sociate and Covered Entity) accreditation programs...ne for public comment is Feb. 10, 2008., (LOGO: ...
...N, Va., Dec. 20 MCG Capital,Corporation (Nasdaq: ...ferred,equity investment to support the acquisitio...ld & Lamb is a medical-financial services company ...tion industry,since 2001. Having completed in exce...
Other Medicine News:Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 2Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 3Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 4Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 5Health News:Reconstruction surgery rarely discussed with breast cancer patients 2Health News:ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily) 2Health News:Sharp HealthCare Foundation Reaches $50 Million Goal 2Health News:Sharp HealthCare Foundation Reaches $50 Million Goal 3Health News:URAC Calls for Comments on Changes to Standards for Health Web Site, HIPAA Privacy and Security Accreditation Programs 2Health News:MCG Capital Invests in Gould & Lamb 2
Atria 3100 ECG
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
Medicine Products: